Orphenadrine
Back to searchMolecule Structure
Scientific Name
Orphenadrine
Description of the Drug
Orphenadrine is a muscarinic antagonist used as an adjunct for the symptomatic relief of musculoskeletal pain and discomfort.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01173
http://www.drugbank.ca/drugs/DB01173
Brand Name(s)
Not Available
Company Owner(s)
Impax Pharmaceuticals, Sandoz Inc, Sagent Pharmaceuticals Inc, Lupin Inc, Ascot Hosp Pharmaceuticals Inc Div Travenol Laboratories Inc, Watson Laboratories Inc, Hikma Pharmaceuticals Usa Inc, Anda Repository Llc, Pai Holdings Llc Dba Pharmaceutical Associates Inc, Bayshore Pharmaceuticals Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium channel alpha subunit | PROTEIN FAMILY | BLOCKER | CHEMBL2331043 |
| Histamine H1 receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL231 |
| Glutamate [NMDA] receptor | PROTEIN COMPLEX GROUP | ANTAGONIST | CHEMBL2094124 |
| Norepinephrine transporter | SINGLE PROTEIN | INHIBITOR | CHEMBL222 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL28727 | ||||
| PharmGKB | PA450715 | ||||
| Human Metabolome Database | HMDB0015304 | ||||
| DrugBank | DB01173 | ||||
| PubChem: Thomson Pharma | 14750489 | ||||
| PubChem | 4601 | ||||
| Mcule | MCULE-7320950210 | ||||
| LINCS | LSM-1630 | ||||
| Nikkaji | J4.888G | ||||
| BindingDB | 50062614 | ||||
| EPA CompTox Dashboard | DTXSID3023396 | ||||
| DrugCentral | 1999 | ||||
| Brenda | 144774 | ||||
| ChemicalBook | CB1397020 | ||||
| Guide to Pharmacology | 7251 | ||||
| rxnorm | ORPHENGESIC | ORPHENADRINE HYDROCHLORIDE | NORGESIC | ORPHENADRINE | ORPHENADRINE CITRATE |
| KEGG Ligand | C07935 | ||||
| ChEBI | 7789 |
